Clinical trial NCT04078204: A Clinical Study on the Treatment of Cerebral Small Vascular Disease
Official title: A Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Dl-3-Butylphthalide on the Treatment of Small Cerebral Vessel Disease
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cerebral Small Vessel Diseases
Keywords: Butylphthalide
Cerebral Small Vessel Diseases
Clinical Study
Lead sponsor: Peking Union Medical College Hospital
Sponsor class: OTHER
First posted: 2019-09-04
Enrollment: 300
Sex: ALL
Minimum age (years): 50
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is designed to evaluate the safety and efficacy of butylphthalide (NBP) in the treatment of cerebral small vessel disease through a multicenter, randomized,double-blind, placebo-controlled study. Butylphthalide Soft Capsule and placebo were prescribed to the experimental group and the control group for a period of 24-months, respectively. After that, the experimental group and the control group were given Butylphthalide Soft Capsule for 6 months.

Detailed description: Butylphthalide can protect mitochondrial function and inhibit neuronal apoptosis by significantly increasing the activity of mitochondrial ATP complex enzyme and mitochondrial respiratory chain complex enzyme IV, improving the fluidity of mitochondrial membrane and maintaining mitochondrial membrane potential. Butylphthalide can reconstruct microcirculation and protect mitochondria, which can protect neurovascular units in an all-round way. Findings from previous studies have shown that butylphthalide can improve the ability of daily living of patients with ischemic cerebrovascular disease and can enhance cognitive function of patients diagnosed as subcortical vascular cognitive impairment no dementia.

Eligibility criteria: Inclusion Criteria:

1. 50-80 years of age;
2. all subjects with a culture level of primary school or above;
3. Cerebral MRI demonstrated that patients with white matter hyperintense signal of vascular origin (Fazekas score≥ 2 points) and lacunar lesions (≥ 2);
4. Consistent with at least one of the following clinical manifestations: (1)Subjects with a history of lacunar stroke syndrome more than 6-months before study initiation(Patients should have one of the traditional clinical lacunar syndromes and a new symptomatic lesion with a diameter of less than 20mm observed in subcortical white matter or basal ganglia), without a stenosis of greater than 50% in ipsilateral internal carotid artery or middle cerebral artery.) (2)Subjects with cognitive impairment (impairment involving memory and/or other cognitive domains and lasting for at least 3-months) have at least one domain rating of CDR \> 0.5. Cognitive impairment and cerebrovascular disease are likely to have a causal relationship, showing sudden or fluctuating cognitive decline with ladder-like progress.
5. Modified Rankin score ≤ 3 points; MMSE ≥ 10 points;
6. Subjects have stable and reliable caregivers who must be able to communicate frequently with the subjects (at least 4 days a week, at least 2 hours a day). The caregivers will help the subjects participate in the whole process of the study. The caregiver must accompany the subjects to participate in the research visits, and must fully interact and communicate with the subjects in order to provide valuable information for CIBIC-plus, ADL, NPI and other scales.
7. Female patients are menopausal women (menopause ≥ 24 weeks), or have undergone surgical sterilization or have agreed to take effective contraceptive measures during the trial period.
8. If patients use antipsychotic drugs (risperidone, quetiapine or olanzapine), anti-anxiety and depression drugs, sedative and hypnotic drugs and other drugs before screening, they need to take them stably for at least one month before screening, and try to maintain the dose stability during the research process. Sedative and hypnotic drugs such as zopiclone, alprazolam and estazolam may be used when necessary, but they should not be used within 8 hours of visiting time.
9. Consent to participation in this study with the written informed consents obtained from all patients or their legal surrogates.

Exclusion Criteria:

1. New onset cerebral infarction or intracranial hemorrhage within 6 months;
2. Complicated with cerebral cortical infarction or cerebral hemorrhage,hydrocephalus and other white matter lesions of non-vascular origin (multiple sclerosis, carbon monoxide poisoning encephalopathy, etc.);
3. Systemic diseases that may be responsible for cognitive impairment (such as liver and kidney dysfunction, endocrine diseases, vitamin deficiency, systemic autoimmune diseases, etc.);
4. Depression and depression related conditions (Hamilton Depression Scale score ≥ 17 points), or other unrelated serious mental disorders (schizophrenia, bipolar affective disorder or delirium) or serious neurological diseases (such as central nervous system infection (for example AIDS, syphilis), Creutzfeldt-Jakob disease, Huntington's chorea and primary Parkinson's disease,Lewy body dementia,corticobasal ganglia degeneration, brain trauma, epilepsy, brain tumors (with an exception of patients with meningioma which could not attribute to cognitive impairment based on the judgement of the researchers.)
5. Those who use other drugs that affect the safety or efficacy evaluation of the tested drugs and disagree with withdrawal, such as NBP,cholinesterase inhibitors (Arizona, Essene, Galantamine, Huperzine A Tablets, Benzhexol Hydrochloride etc.), N-methyl-D-aspartic acid (NMDA) antagonists (such as Memantine, Amantadine, Ketamine, etc.);
6. Patients allergic or intolerant to butylphthalide (NBP) ;
7. Patients with severe cardiac,pulmonary and renal insufficiency (creatinine \> 2.0 mg/dl or 178umol/L), severe liver dysfunction (ALT or AST \>3 times of upper limit of the normal value), any malignancies and those with a life expectancy less than 2 years;
8. Patients with Coagulation dysfunction or thrombocytopenia (platelet \< 100 \*10\^9/L);
9. Contraindication for MR examination.
10. Women during pregnancy and lactation period or plan to be pregnant.
11. Patients who are participating in other interventional clinical studies or have participated in other interventional clinical studies in the past three months;
12. Patients who could not be followed up as required during the study period;
13. Patients unable to complete neuropsychological evaluations due to illiteracy or irreparable audiovisual impairment;
14. Refractory hypertension: blood pressure ≥180/110 mmHg;
15. The subjects are the investigators and immediate family members participating in the study, employees and immediate family members of embip.

Primary outcomes:
measure: The occurrence of the composite endpoint
timeFrame: 30 months
measure: Change of CIBIC-Plus score
timeFrame: 30 months
measure: Change of ADAS-cog score
timeFrame: 30 months
measure: Volume changes of white matter hyperintensities observed on cerebral MRI
timeFrame: 30 months
Secondary outcomes:
measure: The proportion of participants with an increase of mRS by≥ 2, or mRS≥5 for severe disability
timeFrame: 30 months
measure: The proportion of participants with new onset dementia。New onset dementia meets the following three criteria:
timeFrame: 30 months
measure: The proportion of participants with death due to any known or unknown cause
timeFrame: 30 months
measure: Changes of the gait speed in three-meter walktest
timeFrame: 30 months
measure: Changes in the number of silent brain infarcts
timeFrame: 30 months
measure: Changes in the number of cerebral microbleeds
timeFrame: 30 months
measure: Evolution of brain volumes (gray matter, white matter and CSF volumes)
timeFrame: 30 months
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
Study officials:
References: